| | Ranbaxy Laboratories has announced the launch of BONISTA- Teriparatide injection (recombinant human parathyroid hormone) for the treatment of Osteoporosis, in collaboration with Virchow Biotech, Hyderabad, India. Ranbaxy is the first company to launch this bio generic product in the world.
The product has been indigenously researched at Virchow Biotech and developed with and from the Department of Science and Technology, Government of India.
Virchow Biotech, part of the Hyderabad based Rs 600 crore Virchow Group, engages in research, development, manufacture and marketing of a wide range of unique classical biologicals and high value recombinant bio-generie products for serious life-threatening diseases at affordable prices. Established in 2001, Virchow Biotech produces over 15 biological products in state of the art production facilities equipped to manufacture topical biologicals, recombinants and parenteral biopharmaceuticals. The facilities have been audited and certified by various regulatory agencies for their conformance to current Good Manufacturing Practices (cGMPs). Virchow Biotcch also monitors and conducts large multi-centric clinical trials and is a Government of India recognized R&D Centre.
The company made this announcement during the trading hours today, 03 April 2008.
|
No comments:
Post a Comment